Please assess the completion status of the following clinical trial:

Trial Title: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years of age~2. Histologic proof of malignancy currently undergoing a course of RT (with or without chemotherapy) to a dose of ≥ 5000 cGy using 1.60 to 2.20 Gy per fraction. Note: At least one third of the oral cavity mucosa must be included in the radiation therapy fields.~3. ≥ 4 oral pain felt to be related to mucositis for which the patient wants relief as measured by the Numeric Measure of Oral Pain. Note: An oral exam confirming the presence of mucositis should be performed by the enrolling clinician in addition to patient feedback.~4. Ability to complete questionnaire(s) independently or with assistance~5. ECOG Performance Status 0, 1 or 2.~6. Provide informed written consent.~7. Willingness to return to enrolling institution for follow-up.~Exclusion Criteria:~1. Known allergy to doxepin, tricyclic antidepressants, or any known component of the drug formulation~2. Use of a tricyclic antidepressant or monoamine oxidase inhibitor within the 2 weeks prior to registration~3. Current untreated or unresolved oral candidiasis or oral HSV infection~4. Current untreated narrow angle glaucoma~5. Current untreated urinary retention ≤ 6 weeks prior to registration~6. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens~7. Any of the following because this study involves a study agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:~   * Pregnant women~  * Nursing women~  * Men or women of childbearing potential who are unwilling to employ adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).